Drug General Information |
Drug ID |
D09PUW
|
Former ID |
DNC013259
|
Drug Name |
Bis(5-methoxybenzo[b]furan-2-yl)methanone
|
Drug Type |
Small molecular drug
|
Indication |
Discovery agent
|
Investigative |
[1]
|
Structure |
|
Download
2D MOL
3D MOL
|
Formula |
C19H14O5
|
Canonical SMILES |
COC1=CC2=C(C=C1)OC(=C2)C(=O)C3=CC4=C(O3)C=CC(=C4)OC
|
InChI |
1S/C19H14O5/c1-21-13-3-5-15-11(7-13)9-17(23-15)19(20)18-10-12-8-14(22-2)4-6-16(12)24-18/h3-10H,1-2H3
|
InChIKey |
HEAUVWMQZFRPLK-UHFFFAOYSA-N
|
PubChem Compound ID |
|
Target and Pathway |
Target(s) |
Beta platelet-derived growth factor receptor |
Target Info |
Inhibitor |
[1]
|
KEGG Pathway
|
MAPK signaling pathway
|
Ras signaling pathway
|
Rap1 signaling pathway
|
Calcium signaling pathway
|
Cytokine-cytokine receptor interaction
|
PI3K-Akt signaling pathway
|
Focal adhesion
|
Gap junction
|
Regulation of actin cytoskeleton
|
HTLV-I infection
|
Pathways in cancer
|
MicroRNAs in cancer
|
Glioma
|
Prostate cancer
|
Melanoma
|
Central carbon metabolism in cancer
|
Choline metabolism in cancer
|
PANTHER Pathway
|
Angiogenesis
|
PDGF signaling pathway
|
Pathway Interaction Database
|
Signaling events mediated by PTP1B
|
Beta3 integrin cell surface interactions
|
S1P3 pathway
|
Nectin adhesion pathway
|
Signaling events mediated by TCPTP
|
SHP2 signaling
|
S1P1 pathway
|
Urokinase-type plasminogen activator (uPA) and uPAR-mediated signaling
|
PDGFR-beta signaling pathway
|
Validated targets of C-MYC transcriptional repression
|
PDGF receptor signaling network
|
Reactome
|
PIP3 activates AKT signaling
|
Constitutive Signaling by Aberrant PI3K in Cancer
|
RAF/MAP kinase cascade
|
WikiPathways
|
Regulation of Actin Cytoskeleton
|
MAPK Signaling Pathway
|
Osteoblast Signaling
|
Focal Adhesion
|
PIP3 activates AKT signaling
|
PDGF Pathway
|
Signaling Pathways in Glioblastoma
|
Signaling by PDGF
|
References |
REF 1 | Bioorg Med Chem. 2007 Mar 1;15(5):2187-97. Epub 2006 Dec 12.Inhibition of FLT3 and PDGFR tyrosine kinase activity by bis(benzo[b]furan-2-yl)methanones. |